Solidseq CGP Plus (>550 Genes Panel + TMB + MSI + HRD Score) Test: Booking, Price, and Results
About Solidseq CGP Plus (>550 Genes Panel + TMB + MSI + HRD Score) Test: Booking, Price, and Results
| Field | Value |
|---|---|
| Also Known As | Comprehensive Genomic Profiling (CGP) Plus, Tumour Genomic Panel, Solidseq Tumour Profiling, Solid Tumour CGP Panel |
| Sample Type | FFPE Tissue Block (formalin-fixed paraffin-embedded preserved tumour tissue) |
| Fasting Required | No fasting required |
| Report Time | 30 days |
| Recommended For | Adults with advanced or metastatic solid tumours |
| Price | Starting at ₹1,08,000 |
What Is a Solidseq CGP Plus (>550 Genes Panel + TMB + MSI + HRD Score) Test?
The Solidseq CGP Plus (>550 genes panel + TMB + MSI + HRD score) test is an advanced cancer genomic profiling test that analyses over 550 cancer-related genes in a single panel. It uses next-generation sequencing (NGS), a technology that reads the DNA of tumour tissue in great detail. The test also measures three key genomic signatures: tumour mutational burden (TMB), microsatellite instability (MSI), and homologous recombination deficiency (HRD) score. It is typically prescribed by oncologists for patients with advanced or metastatic solid tumours. This test is also known as comprehensive genomic profiling (CGP) plus, tumour genomic panel, Solidseq tumour profiling, or solid tumour CGP panel. The sample used is a preserved tumour tissue block, known as an FFPE tissue block.
What Does a Solidseq CGP Plus (>550 Genes Panel + TMB + MSI + HRD Score) Test Measure?
This test analyses both individual gene mutations and broader genomic signatures to guide cancer treatment decisions. The three key genomic signatures measured are described below, followed by the full list of genes tested and their purpose:
| Signature | What It Measures | Why It Matters |
|---|---|---|
| TMB (Tumour Mutational Burden) | Total number of mutations per coding region of the tumour genome, measured in mutations per megabase (mut/Mb) | TMB-High (10 or more mut/Mb) may indicate potential benefit from immunotherapy |
| MSI (Microsatellite Instability) | Presence of errors in short repeated DNA sequences, reflecting DNA mismatch repair function | MSI-High tumours may respond well to immune checkpoint inhibitor therapy |
| HRD Score (Homologous Recombination Deficiency) | Measures large-scale DNA changes including loss of heterozygosity, large-scale state transitions, and telomeric allelic imbalance | HRD-Positive score may indicate sensitivity to PARP inhibitors and platinum-based chemotherapy |
The panel covers more than 550 cancer-related genes. Below are the key gene categories and representative genes:
| Gene Category | Genes Included | Purpose of Testing |
|---|---|---|
| Oncogenes (cancer-driving genes) | EGFR, KRAS, BRAF, PIK3CA, ALK, RET, MET, ERBB2, HRAS, NRAS, AKT1, AKT2, AKT3, RAF1, ARAF, MAP2K1, MAP2K2, MYC, MYCN, MYCL, CDK4, CDK6, MDM2, FLT1, KDR, KIT | Identify gene changes that can be targeted by approved therapies |
| Tumour Suppressor Genes | TP53, BRCA1, BRCA2, APC, PTEN, RB1, NF1, NF2, VHL, TP73, CDKN2A, CDKN2B, CDKN1A, CDKN1B, CDKN1C, FAT1, FBXW7 | Assess DNA repair deficiencies and prognostic factors |
| DNA Repair Pathway Genes | ATM, ATR, CHEK1, CHEK2, PALB2, RAD51B, RAD51C, RAD51D, RAD50, RAD52, RAD54L, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL, FANCM, MLH1, MSH2, MSH3, MSH6, PMS1, PMS2, MUTYH, BRIP1, BLM, MRE11, NBN, RECQL4 | Evaluate HRD status and mismatch repair defects |
| Cell Cycle Regulators | CCND1, CCND2, CCND3, CCNE1, CDK2, CDK7, CDK8, CDK12, CDKN2C, CKS1B, AURKA, AURKB, AURKC, CENPA | Identify potential CDK inhibitor sensitivity |
| Growth Factor Receptors | FGFR1, FGFR2, FGFR3, FGFR4, PDGFRA, PDGFRB, EGFR, ERBB2, ERBB3, ERBB4, IGF1R, CSF1R, DDR1, DDR2, EPHA2, EPHA3 | Guide FGFR, EGFR, and tyrosine kinase inhibitor selection |
| Fusion and Rearrangement Genes | NTRK1, NTRK2, NTRK3, ROS1, ALK, RET, NRG1, ETV1, ETV4, ETV5, ETV6, TMPRSS2, ERG, NUTM1, NAB2 | Detect gene fusions for targeted therapy eligibility |
| Immune Checkpoint and Immunotherapy Genes | CD274 (PD-L1), PDCD1LG2, B2M, JAK1, JAK2, JAK3, CTLA4, CD22, CD38, CD44, CD58, CD74, CD79A, CD79B, HLA-A, HLA-B, HLA-C, IDO1, IDO2, IFNGR1, IFNGR2, NLRC5, CIITA, RFX5, RFXAP, TAP1, TAP2, TAPBP, SOCS1, STAT1, STAT3, STAT5B, IRF1 | Predict immunotherapy response and immune evasion mechanisms |
| Epigenetic Modifiers | ARID1A, ARID1B, ARID2, ARID5B, KMT2A, KMT2B, KMT2C, KMT2D, EZH2, DNMT1, DNMT3A, DNMT3B, DOT1L, CREBBP, EP300, SETD2, SETBP1, KDM5C, KDM6A, PBRM1, SMARCA4, SMARCB1, ASXL1, ASXL2, BAP1, PHF6, CHD2, CHD4, CHD8, DAXX, HIST1H3B, HIST1H3C, HIST1H3D, HIST1H3E, HIST1H3F, HIST1H3G, HIST1H3H, HIST1H3I, HIST1H3J, HIST2H3C, H3F3A, H3F3B, HIST1H1C | Assess tumour biology and potential therapy targets |
| Signalling Pathway Genes | PIK3CA, PIK3CB, PIK3CD, PIK3R1, PIK3R2, MTOR, STK11, KEAP1, NFE2L2, RHOA, RHEB, RICTOR, RPTOR, RASA1, NF1, LATS1, LATS2, AXIN1, AXIN2, CTNNB1, APC, NOTCH1, NOTCH2, NOTCH3, NOTCH4, SMO, PTCH1, SMAD2, SMAD3, SMAD4, TGFBR2, ACVR1, ACVR1B, ACVR2A, HGF, HIF1A, SRC, LYN, SYK, BTK, PAK1, PAK3, PAK7, PLCG1, CRKL, MAPK1, MAP3K1, MAP2K4, SOS1, RIT1, RAS-related genes | Evaluate PI3K/AKT/mTOR, Wnt, Hedgehog, and MAPK pathway alterations |
| Transcription Factors and Others | FOXA1, FOXA2, FOXL2, FOXO1, FOXP1, GATA3, GATA6, GNA11, GNA13, GNAQ, GNAS, ESR1, AR, RUNX1, PAX5, MYB, TCF7L2, TCF12, TBX3, SOX9, SOX17, SPOP, MEN1, MECOM, NCOA2, NCOR1, KLF4, MAX, MED12, NFKB2, NFKBIA, NKX2, NKX3, LMO1, DLX1, JUN, CIC, QKI, REST, REL, EIF4A2, ELF3, GPS2, FUBP1, PSIP1, TBL1XR1, BCOR, CBFB, CARD11, BIRC3, LRP1B, AMER1 | Guide tumour biology characterisation and identify novel therapy targets |
| Other Clinically Relevant Genes | ABL1, ABL2, ABR, ABRAXAS1, ADGRA2, AJUBA, AKAP9, ALOX12B, ALOX15B, ANKRD11, ANKRD26, APLNR, ARFRP1, ARHGAP26, ARHGAP35, ATRX, BTG1, BTG2, CASR, CASP8, CFTR, COL17A1, CPA1, CRBN, CRLF2, CSAD, CSNK1A1, CTCF, CUL3, CUL4A, CUL4B, CUX1, CYLD, DCUN1D1, DDX3X, DDX5, DEFB134, DHX9, DICER1, DIS3, DIS3L2, DNAJB1, DPYD, E2F3, EED, EGFL7, ELOC, FAS, FGF19, LAMP1, LZTR1, MCL1, MDM4, MGA, MGMT, MRE11, MYH9, NSD1, NSD3, NUP93, NPM1, P2RY8, PARP1, PCBP1, PIAS3, PIAS4, PIM1, POLE, POLQ, PPM1D, PPP2R1A, PPP2R2A, PPP4R2, PPP6C, PRKAR1A, PSMA1, PSMB5, PSMD1, PSMG2, PTPN11, PTPRD, PTPRO, PTPRS, PTPRT, PTK2, RAC1, RAD21, RBM10, RFX5, RFXAP, RMF43, RPL22, RPL5, RPS6KA4, RPS6KB1, RPS6KB2, RRM1, RSPO2, SARSF2, SRSF2, SERPINB3, SERPINB4, SF3B1, SLC34A2, SMC1A, SMC3, SMG1, STAG1, STAG2AXL, TAF1, TAF3, TET2, TGFBRN, TP53BP1, CDC73, CDH1, CRBN, IL6ST, LTK | Covers additional cancer-associated genes for a complete mutational landscape |
Why Is a Solidseq CGP Plus (>550 Genes Panel + TMB + MSI + HRD Score) Test Done?
This test is ordered when a detailed molecular picture of a patient's tumour is needed to guide treatment. It helps oncologists choose the most appropriate therapy based on the specific genetic changes found in the cancer.
Common Symptoms That May Require This Test
The test is not ordered based on symptoms alone; it is prescribed after a cancer diagnosis. The following clinical situations commonly prompt referral for this test:
- Diagnosis of an advanced or metastatic solid tumour
- Cancer that has stopped responding to standard treatment
- Disease progression despite initial therapy
- Rare or unusual cancer types where standard treatment options are limited
- Cancer of unknown primary origin, where the original site of cancer is unclear
- Need to assess eligibility for targeted therapy or immunotherapy
Conditions This Test Can Help Detect
This test does not diagnose cancer. Instead, it profiles the genomic characteristics of an already diagnosed cancer. It can help assess:
- Actionable gene mutations across a wide range of solid tumours (lung, breast, colorectal, ovarian, prostate, pancreatic, and others)
- Tumours with high TMB that may respond to immune checkpoint inhibitors
- MSI-High tumours, including those linked to Lynch syndrome
- HRD-Positive tumours in ovarian, breast, prostate, and pancreatic cancers
- Eligibility for clinical trials requiring specific genomic markers
- Mechanisms of drug resistance in tumours that have progressed on prior therapy
How to Prepare and What to Expect
This test does not require any special preparation at home. Here is what to know before the sample is submitted.
Do You Need to Fast?
No fasting is required for this test. The sample is tumour tissue, not blood, so dietary restrictions do not apply. Always follow specific instructions provided by your doctor.
Practical Tips Before Your Test
There are a few important things to arrange before submitting your sample:
- Bring a detailed clinical history, including your symptoms, previous test results, and family history, as this is required for the test
- Inform your oncologist about all prior treatments, including chemotherapy and radiation, as treatment history can affect how results are interpreted
- Confirm that an adequate tumour tissue specimen (FFPE block) is available from a recent biopsy or surgical procedure
- Inform your doctor about all current medications, as some treatments may alter the tumour's genomic profile
Step-by-Step Procedure
The Solidseq CGP Plus (>550 genes panel + TMB + MSI + HRD score) test procedure involves several stages from tissue collection to report generation:
- Your oncologist evaluates your cancer type and stage to decide whether this test is appropriate for your situation.
- A tumour tissue sample is collected, usually from a previous biopsy or surgical procedure. If no archived tissue is available, a new biopsy may be arranged.
- The tissue is preserved using a method called formalin-fixing and paraffin-embedding (FFPE), which protects it for laboratory analysis.
- The FFPE tissue block is packed at ambient temperature (18 to 28°C) and dispatched to the Lupin Diagnostics laboratory.
- At the laboratory, DNA or RNA is extracted from the tissue and prepared for next-generation sequencing (NGS).
- Sequencing data is analysed by specialist bioinformatics tools and reviewed by pathologists. Results are typically ready within 30 days and shared with your oncologist.
Factors That Can Affect Accuracy
Several factors can influence the quality and reliability of results:
- Low tumour content in the tissue sample (too few cancer cells relative to normal cells)
- Poor DNA quality due to prolonged storage or improper fixation of the tissue
- Samples stored for more than six months may have a lower test success rate
- Tumour heterogeneity, meaning the cancer may have different genetic profiles in different parts or sites, and one sample may not reflect the full picture
- Prior cancer treatments may alter the tumour's genomic landscape and affect mutation detection
Understanding Your Solidseq CGP Plus (>550 Genes Panel + TMB + MSI + HRD Score) Test Results
Results from this test are detailed and require specialist interpretation. Your oncologist or a molecular tumour board will review findings in the context of your cancer type, stage, and overall health. The table below summarises how key findings are generally classified:
| Parameter | Result | Interpretation |
|---|---|---|
| TMB (Tumour Mutational Burden) | High (≥10 mutations/Mb) | May indicate eligibility for immune checkpoint inhibitor therapy such as pembrolizumab. |
| TMB (Tumour Mutational Burden) | Low (<10 mutations/Mb) | Less likely to benefit from immunotherapy based on TMB status alone. |
| MSI (Microsatellite Instability) | MSI-High (MSI-H) | More likely to respond to immunotherapy; may suggest Lynch syndrome. |
| MSI (Microsatellite Instability) | Microsatellite Stable (MSS) / MSI-Low (MSI-L) | Less likely to benefit from immunotherapy based on MSI status alone. |
| HRD Score (Homologous Recombination Deficiency Score) | Positive (≥42) | May indicate sensitivity to PARP inhibitors and platinum-based agents. |
| HRD Score (Homologous Recombination Deficiency Score) | Negative (<42) | Less likely to benefit from HRD-targeted therapies. |
| Gene Alterations | Pathogenic / Likely Pathogenic | May indicate eligibility for targeted therapy. |
| Gene Alterations | Variant of Uncertain Significance (VUS) | Clinical significance is currently uncertain. |
| Gene Alterations | Benign / Likely Benign | No known clinical significance. |
Disclaimer: These ranges are general guidelines. Your doctor will interpret your results based on your age, health history, and other factors. Always consult a qualified healthcare professional for personalised medical advice.
Results During Special Conditions
Certain circumstances may affect how results should be read:
- Older tissue samples or specimens with low tumour cell content may produce inconclusive results, as DNA quality degrades over time.
- Patients who have already received cancer treatments may show resistance mutations that were not present at the time of initial diagnosis, as tumours can evolve under therapy.
- Because a single biopsy sample captures only one area of the tumour, some genetic changes present elsewhere in the cancer may not be detected.
How to Maintain Healthy Levels
This test measures tumour genomic features rather than routine blood parameters, so "normal levels" do not apply in the conventional sense. The following guidance is relevant after receiving results:
- Follow your oncologist's recommendations regarding targeted therapy, immunotherapy, or clinical trial enrolment based on your genomic findings.
- If germline (inherited) mutations such as BRCA1 or BRCA2 are identified, consider genetic counselling to assess implications for family members.
- Attend all scheduled follow-up appointments so your oncologist can monitor treatment response and assess whether repeat testing is needed if the cancer progresses.
Lupin Diagnostics Solidseq CGP Plus (>550 Genes Panel + TMB + MSI + HRD Score) Test Price
The Solidseq CGP Plus (>550 genes panel + TMB + MSI + HRD score) test cost starts at ₹1,08,000 at Lupin Diagnostics. This test requires a visit to a hospital; home collection is not available for this test, as it involves submission of a preserved tumour tissue block. The table shows indicative prices:
| City | Approximate Price (₹) |
|---|---|
| Mumbai | 108000 |
| Pune | 108000 |
| Bangalore | 108000 |
| Chennai | 108000 |
Disclaimer: Prices are indicative and may vary by location. Please confirm the current price at the time of booking.
How to Book
Follow these steps for Solidseq CGP Plus (>550 genes panel + TMB + MSI + HRD score) test online booking:
- Select the test on the Lupin Diagnostics website.
- Choose your city and preferred centre location.
- Visit the centre at your scheduled time for sample submission; carry the FFPE tissue block and your complete clinical history as required.
- Receive your report via email or WhatsApp within 30 days.
Frequently Asked Questions
Comprehensive genomic profiling (CGP) is a molecular testing approach that uses next-generation sequencing to examine a large number of cancer-related genes in a single test. It detects multiple types of genetic changes simultaneously, including single nucleotide variations, insertions, deletions, copy number variations, and gene fusions. The Solidseq CGP Plus (>550 genes panel + TMB + MSI + HRD score) test is one such panel.
This test is generally recommended for patients with advanced or metastatic solid tumours, particularly those who have already received standard therapies or whose cancer has progressed. It is also useful for patients with rare cancers, cancers of unknown primary origin, or those being considered for clinical trials that require detailed genomic profiling.
The sample for this test is a preserved tumour tissue block (FFPE block) from a previous biopsy or surgical procedure. No blood draw is required. If no archived tissue is available, your oncologist may arrange a new biopsy. The block is then submitted to the laboratory for analysis.
At Lupin Diagnostics, the report turnaround time for this test is 30 days. The test results will be delivered directly via email or WhatsApp.
An actionable mutation means a genetic change has been identified in the tumour that may be targeted by an approved drug or a therapy available in a clinical trial. Your oncologist will assess whether a matched treatment is suitable based on your cancer type and overall health. Finding an actionable mutation does not guarantee that a specific therapy will be effective.
This test is primarily designed to analyse mutations in tumour tissue. However, some detected mutations may suggest an inherited (germline) origin. If this is the case, your doctor may recommend follow-up germline testing and genetic counselling to assess the implications for you and your family members.
No, Solidseq CGP Plus (>550 genes panel + TMB + MSI + HRD score) test home collection is not available. The test requires an FFPE tumour tissue block, which must be obtained through a medical procedure such as a biopsy or surgery. Please coordinate with your oncologist for sample submission.
Solidseq CGP Plus (>550 Genes Panel + TMB + MSI + HRD Score) Test: Booking, Price, and Results
